148 related articles for article (PubMed ID: 29849821)
21. Modulation of EZH2 Activity Induces an Antitumoral Effect and Cell Redifferentiation in Anaplastic Thyroid Cancer.
de Mello DC; Saito KC; Cristovão MM; Kimura ET; Fuziwara CS
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175580
[TBL] [Abstract][Full Text] [Related]
22. Novel role of ASH1L histone methyltransferase in anaplastic thyroid carcinoma.
Xu B; Qin T; Yu J; Giordano TJ; Sartor MA; Koenig RJ
J Biol Chem; 2020 Jun; 295(26):8834-8845. PubMed ID: 32398261
[TBL] [Abstract][Full Text] [Related]
23. Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells.
Aiello A; Pandini G; Frasca F; Conte E; Murabito A; Sacco A; Genua M; Vigneri R; Belfiore A
Endocrinology; 2006 Sep; 147(9):4463-75. PubMed ID: 16777971
[TBL] [Abstract][Full Text] [Related]
24. Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance.
Selemetjev SA; Savin SB; Paunovic IR; Tatic SB; Cvejic D
Wien Klin Wochenschr; 2015 May; 127(9-10):337-44. PubMed ID: 25471003
[TBL] [Abstract][Full Text] [Related]
25. MiR-125b inhibits anaplastic thyroid cancer cell migration and invasion by targeting PIK3CD.
Bu Q; You F; Pan G; Yuan Q; Cui T; Hao L; Zhang J
Biomed Pharmacother; 2017 Apr; 88():443-448. PubMed ID: 28122310
[TBL] [Abstract][Full Text] [Related]
26. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.
Smith N; Nucera C
J Clin Endocrinol Metab; 2015 Jan; 100(1):35-42. PubMed ID: 25347569
[TBL] [Abstract][Full Text] [Related]
27. AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947.
Libertini S; Abagnale A; Passaro C; Botta G; Barbato S; Chieffi P; Portella G
Endocr Relat Cancer; 2011 Feb; 18(1):129-41. PubMed ID: 21071467
[TBL] [Abstract][Full Text] [Related]
28. Knockdown of S100A4 blocks growth and metastasis of anaplastic thyroid cancer cells in vitro and in vivo.
Zhang K; Yu M; Hao F; Dong A; Chen D
Cancer Biomark; 2016 Sep; 17(3):281-291. PubMed ID: 27802204
[TBL] [Abstract][Full Text] [Related]
29. Exploring the potential of genome editing CRISPR-Cas9 technology.
Singh V; Braddick D; Dhar PK
Gene; 2017 Jan; 599():1-18. PubMed ID: 27836667
[TBL] [Abstract][Full Text] [Related]
30. The effects of Abemaciclib on cell cycle and apoptosis regulation in anaplastic thyroid cancer cells.
Abutorabi ES; Poursheikhani A; Kashani B; Shamsaiegahkani S; Haghpanah V; Bashash D; Mousavi SA; Momeny M; Ghaffari SH
Mol Biol Rep; 2023 May; 50(5):4073-4082. PubMed ID: 36877344
[TBL] [Abstract][Full Text] [Related]
31. Antisense-miR-21 enhances differentiation/apoptosis and reduces cancer stemness state on anaplastic thyroid cancer.
Haghpanah V; Fallah P; Tavakoli R; Naderi M; Samimi H; Soleimani M; Larijani B
Tumour Biol; 2016 Jan; 37(1):1299-308. PubMed ID: 26289851
[TBL] [Abstract][Full Text] [Related]
32. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer.
Mehta A; Zhang L; Boufraqech M; Zhang Y; Patel D; Shen M; Kebebew E
Endocr Relat Cancer; 2015 Jun; 22(3):319-29. PubMed ID: 25972243
[TBL] [Abstract][Full Text] [Related]
33. Evolving molecularly targeted therapies for advanced-stage thyroid cancers.
Bible KC; Ryder M
Nat Rev Clin Oncol; 2016 Jul; 13(7):403-16. PubMed ID: 26925962
[TBL] [Abstract][Full Text] [Related]
34. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.
Molinaro E; Romei C; Biagini A; Sabini E; Agate L; Mazzeo S; Materazzi G; Sellari-Franceschini S; Ribechini A; Torregrossa L; Basolo F; Vitti P; Elisei R
Nat Rev Endocrinol; 2017 Nov; 13(11):644-660. PubMed ID: 28707679
[TBL] [Abstract][Full Text] [Related]
35. Tolfenamic acid induces apoptosis and growth inhibition in anaplastic thyroid cancer: Involvement of nonsteroidal anti-inflammatory drug-activated gene-1 expression and intracellular reactive oxygen species generation.
Chang JW; Kang SU; Choi JW; Shin YS; Baek SJ; Lee SH; Kim CH
Free Radic Biol Med; 2014 Feb; 67():115-30. PubMed ID: 24216474
[TBL] [Abstract][Full Text] [Related]
36. Epidermal growth factor receptor as a novel therapeutic target in anaplastic thyroid carcinomas.
Ensinger C; Spizzo G; Moser P; Tschoerner I; Prommegger R; Gabriel M; Mikuz G; Schmid KW
Ann N Y Acad Sci; 2004 Dec; 1030():69-77. PubMed ID: 15659782
[TBL] [Abstract][Full Text] [Related]
37. Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regression.
Koo T; Yoon AR; Cho HY; Bae S; Yun CO; Kim JS
Nucleic Acids Res; 2017 Jul; 45(13):7897-7908. PubMed ID: 28575452
[TBL] [Abstract][Full Text] [Related]
38. Myricetin Induces Apoptosis of Human Anaplastic Thyroid Cancer Cells
Jo S; Ha TK; Han SH; Kim ME; Jung I; Lee HW; Bae SK; Lee JS
Anticancer Res; 2017 Apr; 37(4):1705-1710. PubMed ID: 28373432
[TBL] [Abstract][Full Text] [Related]
39. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.
Höpfner M; Sutter AP; Huether A; Schuppan D; Zeitz M; Scherübl H
J Hepatol; 2004 Dec; 41(6):1008-16. PubMed ID: 15582135
[TBL] [Abstract][Full Text] [Related]
40. Inducible CRISPR genome-editing tool: classifications and future trends.
Dai X; Chen X; Fang Q; Li J; Bai Z
Crit Rev Biotechnol; 2018 Jun; 38(4):573-586. PubMed ID: 28936886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]